Title: Long-Term Safety of Brazikumab in the Open-Label Period of a Randomized Phase 2a
Study of Patients With Crohn’s Disease
Version: 2 Date: 13 Nov 2023
Reviewer's report:
Thank you for submitting your paper to this journal.
The usefulness of IL-23 antibody preparations for Crohn's disease has been experienced in
clinical practice, and we believe that it took a lot of effort to compose the paper to discuss the
long-term results of Burakizumab.
Evaluate the discussed safety profile comparison with other IL-23 antibody preparations.
So, your paper is judged to be worthy of acceptance.
Title: Long-Term Safety of Brazikumab in the Open-Label Period of a Randomized Phase 2a
Study of Patients With Crohn’s Disease
Version: 2 Date: 13 Nov 2023
Reviewer's report:
Thank you for submitting your paper to this journal.
The usefulness of IL-23 antibody preparations for Crohn's disease has been experienced in
clinical practice, and we believe that it took a lot of effort to compose the paper to discuss the
long-term results of Burakizumab.
Evaluate the discussed safety profile comparison with other IL-23 antibody preparations.
So, your paper is judged to be worthy of acceptance.
Please review this paper.
user
Title: Long-Term Safety of Brazikumab in the Open-Label Period of a Randomized Phase 2a
Study of Patients With Crohn’s Disease
Version: 2 Date: 13 Nov 2023
Reviewer's report:
Thank you for submitting your paper to this journal.
The usefulness of IL-23 antibody preparations for Crohn's disease has been experienced in
clinical practice, and we believe that it took a lot of effort to compose the paper to discuss the
long-term results of Burakizumab.
Evaluate the discussed safety profile comparison with other IL-23 antibody preparations.
So, your paper is judged to be worthy of acceptance.
assistant